Bright Minds Biosciences Inc.
DRUG Nasdaq Pharmaceutical Preparations Financials FY2020โFY2025
What Bright Minds Biosciences Inc. does
No business description yet.
- Legal name
- BRIGHT MINDS BIOSCIENCES INC.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 40-F ยท Dec 23, 2025
- Accession ยท CIK
- 0001437749-25-038729
0001827401
Revenue and margins
Bright Minds Biosciences Inc. had โ of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Bright Minds Biosciences Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 59.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably Bright Minds Biosciences Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $15.5M | $8.5M | $5.0M | $4.2M | $59.6M |
| Current ratio | 31.4x | 8.1x | 24.3x | 11.3x | 36.1x |
| Quick ratio | 31.4x | 8.1x | 24.3x | 11.3x | 36.1x |
| Total assets | $15.7M | $8.8M | $5.1M | $4.5M | $60.6M |
| Total liabilities | $0.5M | $1.1M | $0.2M | $0.4M | $1.7M |
| Shareholders' equity | $15.2M | $7.7M | $4.9M | $4.1M | $58.9M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | โ / 6 | โ / 6 | โ / 6 | โ / 6 |
| Accruals ratio | โ21.7% | โ12.8% | โ8.8% | โ3.7% | โ14.5% | โ7.8% |
| Altman Z'' | โ | โ | โ | โ | โ | โ |
6 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Research and development | $0.3M | $5.0M | $9.5M | $3.7M | $0.9M | $7.9M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | โ$0.4M | โ$6.8M | โ$11.7M | โ$5.5M | โ$2.1M | โ$8.7M |
| Diluted EPS | โ$0.10 | โ$3.81 | โ$4.74 | โ$1.47 | โ$0.48 | โ |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.01B |
| Cash flow | ||||||
| Cash from operations | โ$0.2M | โ$5.8M | โ$10.6M | โ$5.2M | โ$1.4M | โ$6.2M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | $0.1M | $0.7M | $0.7M | $0.9M | $0.6M | $2.3M |
| Balance sheet | ||||||
| Cash and short-term investments | $0.6M | $15.5M | $8.5M | $5.0M | $4.2M | $59.6M |
| Current assets | $0.7M | $15.7M | $8.7M | $5.1M | $4.4M | $60.6M |
| Current liabilities | โ | $0.5M | $1.1M | $0.2M | $0.4M | $1.7M |
| Total assets | $0.7M | $15.7M | $8.8M | $5.1M | $4.5M | $60.6M |
| Total liabilities | $0.1M | $0.5M | $1.1M | $0.2M | $0.4M | $1.7M |
| Shareholders' equity | $0.5M | $15.2M | $7.7M | $4.9M | $4.1M | $58.9M |
| Returns | ||||||
| Return on equity | โ65.5% | โ86.7% | โ102.3% | โ86.9% | โ45.7% | โ27.7% |
| Return on assets | โ54.3% | โ83.5% | โ95.6% | โ78.6% | โ42.7% | โ26.8% |
| Return on tangible equity | โ65.5% | โ44.9% | โ152.8% | โ111.3% | โ50.3% | โ14.8% |
| Growth | ||||||
| Share count change | โ | โ50.3% | 37.6% | 50.6% | 15.9% | 59.6% |
| Financial health | ||||||
| Current ratio | โ | 31.4x | 8.1x | 24.3x | 11.3x | 36.1x |
| Quick ratio | โ | 31.4x | 8.1x | 24.3x | 11.3x | 36.1x |
| Quality scores | ||||||
| Accruals ratio | โ21.7% | โ12.8% | โ8.8% | โ3.7% | โ14.5% | โ7.8% |
Source: SEC EDGAR XBRL filings (CIK 0001827401). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in CAD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only โ not investment advice. Check the original filings before relying on any figure.